Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Is ‘One to Watch’
FDA-approved LYMPHIR(TM) provides commercial-stage exposure to the oncology market. LYMPHIR(TM) generated $5.6 million in net revenue during the first six…
FDA-approved LYMPHIR(TM) provides commercial-stage exposure to the oncology market. LYMPHIR(TM) generated $5.6 million in net revenue during the first six…
NetworkNewsWire Editorial Coverage: For most of the past decade, counter-drone defense was framed as a capability question. It has quietly…
MindWave Innovations is developing institutional-grade digital asset infrastructure designed to help corporations and institutions hold, manage and generate yield from…
The challenge for steel and other heavy industries is not finding carbon; it is finding carbon that performs reliably without…
Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising. SPARC AI is expanding…
Following completion of the initial phase of its collaboration with OmniAb, VERAXA will engineer the final VXA-222 candidate and conduct…
The United States sits on a significant coal resource base. FASForm produces six commercial outputs from a single coal input:…
WRAP is using newly raised $12 million in growth capital to support planned business expansion and accelerate development of its…
Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising. GPS jamming and spoofing…
VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer cells, developing antibody-based cancer therapies with an emphasis on…